What is a viral-vector vaccine?

A viral-vector vaccine uses a modified virus as a delivery vehicle for genetic instructions that cause the vaccinated person’s cells to make a selected antigen. That antigen is recognised by the immune system, which develops responses that may help protect against future encounters with the disease-causing pathogen. The vector is a carrier; it is not necessarily the pathogen against which vaccination is intended.

The distinction is central to the BPSC question behind this page. A vaccine does not generally work by travelling around the bloodstream to attack and destroy every pathogen directly. Instead, vaccination prepares the body’s own adaptive immune response, including components such as antibodies, T cells and immune memory. There are several vaccine platforms, and the details of how they present antigens vary.

Viral vectors are usually engineered to reduce harmful features or control replication. Some approved vector platforms are non-replicating, while other platforms, such as the recombinant vesicular stomatitis virus used in an Ebola vaccine, are replication-competent. It is therefore inaccurate to declare that every viral-vector vaccine uses an absolutely non-replicating virus.

Step-by-step mechanism of a non-replicating adenovirus vaccine

For adenoviral DNA vectors, genetic instructions may reach the cell nucleus for transcription into messenger RNA. The resulting mRNA is translated into protein by ribosomes. That is different from claiming the vector routinely integrates into the person’s chromosomes. The commonly studied non-replicating adenovirus COVID-19 vectors were designed without a mechanism to integrate the delivered gene into host DNA.

The antigen may be broken down and presented as peptides to immune cells. Immune activation is complex; antibody production alone is not a complete description of a protective response, and protection is not necessarily lifelong or absolute.

The vector versus the pathogen

The target pathogen is the disease-causing microbe against which protection is sought; the vector is a different engineered virus used to carry genetic instructions. For example, the Oxford–AstraZeneca COVID-19 vaccine used a modified chimpanzee adenovirus to carry instructions for the SARS-CoV-2 spike protein. It did not contain a whole live SARS-CoV-2 virus capable of causing COVID-19.

This distinction clarifies the exam alternative that says a vector vaccine involves inserting pathogen-related genetic information into a modified different virus. It is important to say ‘gene encoding an antigen’, not that the entire harmful virus must be inserted intact inside another virus. The vector virus then transfers the instructions to cells.

The scientific explanation also depends on the chosen vector. Adenoviruses, modified vaccinia, measles-virus vectors and vesicular stomatitis virus vectors have different biology. One platform cannot automatically represent the safety, replication pattern or performance of all others.

Innate immunity and adaptive immunity

The innate immune system responds quickly to danger signals using barriers, phagocytes, inflammatory mediators and other broad defence mechanisms. It helps initiate later adaptive responses but is not highly antigen-specific in the same way as mature adaptive immunity.

Adaptive immunity involves lymphocytes that recognise specific antigens. B cells can mature into plasma cells that secrete antibodies. T cells have multiple roles: helper T cells coordinate responses, while cytotoxic T cells can recognise and destroy infected cells presenting appropriate antigen fragments. Memory cells help the body respond more rapidly after a later exposure.

Vaccines train immune recognition without requiring infection with the full virulent target pathogen. Protection still varies by vaccine, disease, host condition, time since immunisation and pathogen evolution. ‘Vaccinated’ does not mean ‘physically impossible to become infected’.

What are antigens, antibodies and memory cells?

An antigen is a structure that can be recognised by components of the adaptive immune system. Viral surface proteins are important antigen examples, but antigens can also derive from internal proteins, bacteria, toxins and other substances. Antibodies are immunoglobulin molecules produced by B-cell-derived plasma cells; they bind particular targets and can neutralise pathogens or help immune clearance.

Memory B cells and memory T cells can persist after vaccination or infection and support faster secondary responses. A high measured antibody level at one moment is not the complete measure of vaccine effectiveness, because functional antibody quality, cell-mediated responses and immunological memory may contribute.

A vaccine antigen cannot be assumed to provide immunity to every variant or every related species. Product-specific clinical evidence and regulatory assessments determine the diseases and populations for which a vaccine is recommended.

Viral-vector, mRNA, inactivated and protein-subunit vaccines compared

The key comparison is that both gene-based vectors and mRNA platforms rely on the host’s protein-making machinery, but they differ in the delivery material and cellular route. Whole-virus vaccines and prepared protein-subunit vaccines deliver antigens more directly. Neither gene delivery nor protein delivery is automatically superior in all contexts.

Non-replicating versus replicating viral vectors

Some vectors are genetically altered so they cannot undergo productive replication in ordinary recipient cells. An example is the non-replicating adenovirus backbone used in certain COVID-19 products. Other vaccine vectors retain the ability to replicate in a limited or controlled manner, potentially amplifying antigen exposure, but their clinical suitability must be evaluated separately.

The recombinant VSV ERVEBO Ebola vaccine is an instructive exception to the idea that ‘viral vector’ always means ‘non-replicating’. CDC describes it as a replication-competent, live attenuated recombinant VSV vaccine. It includes genetic material encoding an Ebola virus glycoprotein but not the whole Ebola virus. It is designed to prevent disease caused by the specified Ebola virus species, not every distinct ebolavirus.

The terms vector replication and target-pathogen infection must not be confused. Even a replicating vaccine vector does not necessarily contain the complete target pathogen.

Examples from India and the world

Covishield / Oxford–AstraZeneca is a historically important example of a chimpanzee adenovirus-based, non-replicating COVID-19 vaccine technology. Other historical adenovirus-vector COVID-19 products included Janssen’s vaccine, Sputnik V and CanSino’s vaccine, subject to different national authorisations and programme histories.

ERVEBO is an example of a recombinant VSV-based Ebola vaccine. Its vector biology differs from non-replicating adenoviral platforms. These examples are useful for mechanism questions, but their present availability cannot be inferred from the dates when they were first deployed. National vaccine schedules and approvals change over time.

Because COVID-19 immunisation guidance is time-sensitive, this exam article does not pretend that a historically studied vaccine is necessarily an option currently offered everywhere. For actual vaccination decisions, readers should consult current official public-health guidance and qualified clinicians.

Safety, adverse events and careful interpretation

Vaccines undergo testing for quality, safety and efficacy before authorisation, with continued adverse-event monitoring afterward. Expected short-term reactions such as injection-site soreness, fatigue or fever reflect activation of immune and inflammatory pathways but are not proof of how much long-term protection a person has gained.

WHO identified a very rare but serious syndrome involving thrombosis with thrombocytopenia after certain adenovirus-vector COVID-19 vaccines, including AstraZeneca-related products. Recognising a rare risk is important; it does not justify a blanket assertion about every vector vaccine or treating unrelated symptoms as proof of causation.

A risk–benefit assessment depends on the particular product, individual circumstances, disease risk and current public-health recommendations. This page is academic study material, not personalised medical advice, and intentionally avoids recommending a particular vaccine to any reader.

Anti-vector immunity and booster strategies

Because the carrier itself is a virus, immune responses may develop against the vector’s proteins. If a person already has relevant immunity from earlier infections or a previous dose, vector neutralisation can sometimes affect antigen delivery. Researchers address this issue through vector selection, modification and certain prime–boost regimens.

Prime–boost refers to a primary vaccine dose followed by one or more later doses intended to strengthen or broaden an immune response. A heterologous prime–boost strategy uses different vaccine platforms or vectors for successive doses; homologous strategies reuse the same platform. The precise efficacy and safety of such strategies must be established for each product and schedule.

The immune system’s response to the carrier and its response to the encoded antigen are related but distinct. A carrier can elicit immunity even though the desired clinical protection is directed at the target pathogen.

Vector vaccines and gene therapy are not the same

Viral vectors are also used in experimental and approved gene-therapy applications, but the objective differs. A viral-vector vaccine presents an antigen to train immune responses against an infectious agent or another specified target. Gene therapy aims to alter or supplement cellular functions for the treatment of a condition, sometimes by delivering a therapeutic genetic sequence.

It is inaccurate to assume that all viral vectors integrate genetic material into human chromosomes. Integration depends on vector design; conventional non-integrating vaccine vectors are designed differently from some integrating gene-delivery systems. This distinction helps evaluate examination statements that portray every vaccine as genetic alteration of the recipient.

Preserved BPSC 69th question with analysis

BPSC 69th Prelims, Q22 (as reproduced in the original CrackTarget note): How do vector vaccines work to provide immunity? (A) By introducing a weakened or inactivated virus into the body; (B) By directly attacking and destroying pathogens; (C) By placing the virus in a modified version of a different virus; (D) By entering directly into the cells and enabling them to create spike proteins.

Answer identified in the original post: (C). The intended mechanism is to use an engineered virus as a vector that delivers antigen-coding genetic material. Wording in alternative (C) is scientifically imprecise if read as inserting a whole disease-causing virus into another virus; the correct mechanism involves inserting a gene encoding an antigen. Option (D) mentions a genuine step—antigen production by host cells—but omits the viral carrier and is specific to spike-based products. That is why (C) best matches the defining idea of a vector vaccine.

Exam preparation should focus on the concept rather than reproducing the ambiguous phrasing as a complete biological definition. The older article’s reasoning is retained and corrected here.

Immunisation, effectiveness and herd effects

Clinical vaccine efficacy is often evaluated by comparing specified outcomes in vaccinated and comparison groups under controlled study conditions. Real-world vaccine effectiveness is estimated in field settings. Results depend on the endpoint—for example, documented infection, symptomatic disease, severe disease or death—and the population and observation period.

Vaccination can reduce transmission for some diseases and vaccines, but protection against infection and protection against severe disease are distinct outcomes. Population-level protection depends on coverage, the pathogen’s transmission characteristics and vaccine performance. It is misleading to attach a single universal ‘herd immunity percentage’ to all viruses and vaccines.

Cold-chain requirements, manufacturing quality, communication and access matter to immunisation programmes alongside the biology of the antigen.

High-yield revision and common errors

1. A vector is a delivery virus, not necessarily the target disease virus.
2. Vector platforms deliver antigen-coding instructions to cells.
3. Host cells produce the antigen and help initiate immunity.
4. B cells, antibodies, helper/cytotoxic T cells and memory cells have different roles.
5. mRNA vaccines do not need a viral-vector carrier to deliver their mRNA.
6. Non-replicating adenovirus vaccines differ from replication-competent VSV vector vaccines.
7. Historical vaccine examples do not establish today’s product availability.
8. Vector immunity can influence repeated use of a vector.
9. All vaccines require product-specific safety evaluation; rare risks should be described accurately.
10. Vaccination trains defence rather than directly killing pathogens as an antibiotic might.

25 original vaccine and immunity MCQs

Open each explanation after choosing an answer. The BPSC question is treated separately above to avoid passing new practice questions off as PYQs.

Frequently asked questions

Do viral vector vaccines contain the disease-causing virus?

They generally carry genetic instructions for a selected antigen, not a complete virulent target pathogen. The precise carrier and construct depend on the product.

Do all viral-vector vaccines use non-replicating carriers?

No. Non-replicating adenoviral examples differ from replication-competent recombinant VSV-based products such as ERVEBO.

How are viral-vector and mRNA vaccines different?

Vectors use a modified virus to deliver coding instructions; mRNA vaccines deliver messenger RNA by another method.

Does a viral-vector COVID vaccine necessarily alter a person’s DNA?

The non-replicating adenoviral COVID-19 vaccines discussed here were not designed to integrate their delivered genes into human chromosomes.

Are all historical vaccine products still used today?

No such conclusion should be drawn. Approvals, schedules and availability change; consult current official guidance.